Binding, Neutralization and Internalization of the Interleukin-13 Antibody, Lebrikizumab.
Angela J OkraglyAya RyuzojiIsabella WulurMontanea DanielsRobert D Van HornChetan N PatelRobert J BenschopPublished in: Dermatology and therapy (2023)
Lebrikizumab is a potent, neutralizing high-affinity antibody with a slow disassociation rate from IL-13. Additionally, lebrikizumab does not interfere with IL-13 clearance. Lebrikizumab has a different mode of action to both tralokinumab and cendakimab, possibly contributing to the clinical efficacy observed by lebrikizumab in Ph2b/3 AD studies.
Keyphrases